search
Back to results

The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect

Primary Purpose

Head and Neck Cancer

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Integra plus STSG
STSG
Sponsored by
Wake Forest University Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Head and Neck Cancer focused on measuring Traumatic Defect, Chronic Wounds

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All subjects who receive a radial forearm free flaps in the included time period, including subjects with head and neck cancer, traumatic defects, chronic wounds, or any other problems that require a radical forearm free flap for reconstruction.
  • Have had a distal, anterograde fasciocutaneous flap
  • Age ≥ 18 years
  • Ability to understand and the willingness to sign an IRB-approved informed consent document.
  • Smokers and tobacco users will be included in this study

Exclusion Criteria:

  • Subjects who have had an osteocutaneous or musculocutaneous flap.
  • Subjects who have a radial forearm flap with a proximal skin flap or subjects that receive a "reverse" radial forearm flap
  • Pregnant women will be excluded due to the lack of clinical studies evaluating INTEGRA template in pregnant women.

Sites / Locations

  • Wake Forest University Health Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Integra and a Split Thickness Skin Graft (STSG)

Split Thickness Skin Graft (STSG)

Arm Description

A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.

reconstruction as dictated by the protocol. They will either receive 1) a 0

Outcomes

Primary Outcome Measures

Number of Participants With Skin Graft Necrosis.
Number of participants with skin graft necrosis.
Vancouver Scar Scale
The Vancouver Scar Scale will measure donor site aesethetic quality and it encompasses 4 separate outcomes to be objectively assessed. Each has been separately reported in the literature for each group in different papers as previously mentioned. We will compare the final score as well as scores within each outcome.On a scale of 1-13; with higher score denoting worse outcome.
Vancouver Scar Scale - Pigmentation
Pigmentation will be measured on the Vancouver Scar Scale. On a scale of 0-2; higher score denoting worse outcome.
Vancouver Scar Scale - Vascularity
Vascularity will be measured on the Vancouver Scar Scale. On a scale of 0-3; higher score denoting worse outcome.
Vancouver Scar Scale - Pliability
Pliability will be measured on the Vancouver Scar Scale. On a scale of 1-5; higher score denoting worse outcome.
Vancouver Scar Scale - Height
Height will be measured on the Vancouver Scar Scale. On a scale of 0-3; higher score denoting worse outcome.
Hand Strength -Lateral Pinch
Functional outcomes will be measured by using strength dynamometers.
Hand Strength -Lateral Pinch
Functional outcomes will be measured by using strength dynamometers.
Hand Strength -Lateral Pinch
Functional outcomes will be measured by using strength dynamometers.
Hand Strength -Lateral Pinch
Functional outcomes will be measured by using strength dynamometers.
Hand Strength - Grip
Functional outcomes will be measured by using strength dynamometers.
Hand Strength - Grip
Functional outcomes will be measured by using strength dynamometers.
Hand Strength - Grip
Functional outcomes will be measured by using strength dynamometers.
Hand Strength - Grip
Functional outcomes will be measured by using strength dynamometers.
Hand Strength- Pincer
Functional outcomes will be measured by using strength dynamometers
Hand Strength- Pincer
Functional outcomes will be measured by using strength dynamometers
Hand Strength- Pincer
Functional outcomes will be measured by using strength dynamometers
Hand Strength- Pincer
Functional outcomes will be measured by using strength dynamometers
Wrist Range of Motion- Flexion
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Wrist Range of Motion- Flexion
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Wrist Range of Motion- Flexion
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Wrist Range of Motion- Flexion
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Wrist Range of Motion- Extension
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Wrist Range of Motion- Extension
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Wrist Range of Motion- Extension
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Wrist Range of Motion- Extension
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Number of Participant With Tendon Exposure
Tendon exposure identified clinically.
Rate of Tendon Exposure
Tendon exposure identified clinically.
Patient Scar Assessment- Paresthesia
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
Patient Scar Assessment- Paresthesia
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
Patient Scar Assessment- Paresthesia
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale. On a scale of 0-100; with higher score denotes worse outcome measure
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale. On a scale of 0-100; with higher score denotes worse outcome measure
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale. On a scale of 0-100; with higher score denotes worse outcome measure
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale. On a scale of 0-100; with higher score denotes worse outcome measure
Percent of Wound Contracture
Planimetry Software will be used to measure and determine percentage of wound contracture
Percent of Wound Contracture
Planimetry Software will be used to measure and determine percentage of wound contracture
Percent of Wound Contracture
Planimetry Software will be used to measure and determine percentage of wound contracture
Skin Pliability
Skin pliability will be measuredusing a Cutometer MPA 580. We plan to measure Pliability (Ua), Elasticity (Ue), Retraction (Ur). Viscoelasticity (Uv), and Extension (Uf).

Secondary Outcome Measures

Full Information

First Posted
November 29, 2016
Last Updated
May 23, 2019
Sponsor
Wake Forest University Health Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT02980601
Brief Title
The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect
Official Title
The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Terminated
Study Start Date
November 2015 (Actual)
Primary Completion Date
August 18, 2017 (Actual)
Study Completion Date
August 6, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University Health Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this research study is to compare the forearm free flap of patients with a traditional split thickness skin graft and those repaired with Integra (a skin substitute that helps to provide wound closure) and a split thickness skin graft. The study team will be looking at the subject's satisfaction with how the skin graft site looks and how well the skin graft site is functioning.
Detailed Description
The radial forearm fasciocutaneous free flap (hereafter referred to as RFFF) was described more than 30 years ago as a fasciocutaneous flap for microsurgical transfer. It was soon after established as a safe and reliable flap for transfer of fascia and cutaneous tissue. Currently, it is used to repair any defect in which a relatively thin island of skin is needed with a fascial strength layer . While the flap itself is very reliable, it leaves a donor site that can be very unsightly and has multiple known complications including loss of pronation, pain, paresthesias, cold intolerance, and skin graft necrosis. The donor site is typically covered with a split thickness skin graft (hereafter referred to as STSG). In an effort to minimize these complications, several groups have described a technique of placing Integra© dermal substitute (hereafter referred to as Integra) underneath the STSG to provide a thicker support and decrease overall morbidity associated with the defect. These studies have shown success in decreasing overall morbidity including increasing range of motion and improving aesthetic quality of the donor site. However, the largest study to date has included only 29 subjects. Furthermore, these studies do not provide a comparative cohort of subjects repaired with a classic STSG to show effectiveness of this technique when compared to a classic repair. Our goal is to perform a prospective study comparing subjects repaired with a classic STSG and those repaired with one step Integra and STSG applied at the same time. These subjects will be evaluated for overall donor site aesthetic quality and functional outcome as described below.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Cancer
Keywords
Traumatic Defect, Chronic Wounds

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Integra and a Split Thickness Skin Graft (STSG)
Arm Type
Experimental
Arm Description
A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
Arm Title
Split Thickness Skin Graft (STSG)
Arm Type
Active Comparator
Arm Description
reconstruction as dictated by the protocol. They will either receive 1) a 0
Intervention Type
Device
Intervention Name(s)
Integra plus STSG
Intervention Description
A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
Intervention Type
Procedure
Intervention Name(s)
STSG
Intervention Description
0.012mm STSG
Primary Outcome Measure Information:
Title
Number of Participants With Skin Graft Necrosis.
Description
Number of participants with skin graft necrosis.
Time Frame
1 year
Title
Vancouver Scar Scale
Description
The Vancouver Scar Scale will measure donor site aesethetic quality and it encompasses 4 separate outcomes to be objectively assessed. Each has been separately reported in the literature for each group in different papers as previously mentioned. We will compare the final score as well as scores within each outcome.On a scale of 1-13; with higher score denoting worse outcome.
Time Frame
1 Year
Title
Vancouver Scar Scale - Pigmentation
Description
Pigmentation will be measured on the Vancouver Scar Scale. On a scale of 0-2; higher score denoting worse outcome.
Time Frame
1 year
Title
Vancouver Scar Scale - Vascularity
Description
Vascularity will be measured on the Vancouver Scar Scale. On a scale of 0-3; higher score denoting worse outcome.
Time Frame
1 year
Title
Vancouver Scar Scale - Pliability
Description
Pliability will be measured on the Vancouver Scar Scale. On a scale of 1-5; higher score denoting worse outcome.
Time Frame
1 year
Title
Vancouver Scar Scale - Height
Description
Height will be measured on the Vancouver Scar Scale. On a scale of 0-3; higher score denoting worse outcome.
Time Frame
1 year
Title
Hand Strength -Lateral Pinch
Description
Functional outcomes will be measured by using strength dynamometers.
Time Frame
Pre-op
Title
Hand Strength -Lateral Pinch
Description
Functional outcomes will be measured by using strength dynamometers.
Time Frame
3 month
Title
Hand Strength -Lateral Pinch
Description
Functional outcomes will be measured by using strength dynamometers.
Time Frame
6 months
Title
Hand Strength -Lateral Pinch
Description
Functional outcomes will be measured by using strength dynamometers.
Time Frame
1 year
Title
Hand Strength - Grip
Description
Functional outcomes will be measured by using strength dynamometers.
Time Frame
pre-op
Title
Hand Strength - Grip
Description
Functional outcomes will be measured by using strength dynamometers.
Time Frame
3 month
Title
Hand Strength - Grip
Description
Functional outcomes will be measured by using strength dynamometers.
Time Frame
6 month
Title
Hand Strength - Grip
Description
Functional outcomes will be measured by using strength dynamometers.
Time Frame
1 year
Title
Hand Strength- Pincer
Description
Functional outcomes will be measured by using strength dynamometers
Time Frame
pre-op
Title
Hand Strength- Pincer
Description
Functional outcomes will be measured by using strength dynamometers
Time Frame
3 month
Title
Hand Strength- Pincer
Description
Functional outcomes will be measured by using strength dynamometers
Time Frame
6 month
Title
Hand Strength- Pincer
Description
Functional outcomes will be measured by using strength dynamometers
Time Frame
1 year
Title
Wrist Range of Motion- Flexion
Description
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Time Frame
pre-op
Title
Wrist Range of Motion- Flexion
Description
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Time Frame
3 month
Title
Wrist Range of Motion- Flexion
Description
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Time Frame
6 month
Title
Wrist Range of Motion- Flexion
Description
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Time Frame
1 year
Title
Wrist Range of Motion- Extension
Description
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Time Frame
pre-op
Title
Wrist Range of Motion- Extension
Description
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Time Frame
3 month
Title
Wrist Range of Motion- Extension
Description
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Time Frame
6 month
Title
Wrist Range of Motion- Extension
Description
Functional outcomes will be measured by using electric goniometers so as to standardize the measurements. Wrist flexion and wrist extension
Time Frame
1 year
Title
Number of Participant With Tendon Exposure
Description
Tendon exposure identified clinically.
Time Frame
6 month
Title
Rate of Tendon Exposure
Description
Tendon exposure identified clinically.
Time Frame
1 year
Title
Patient Scar Assessment- Paresthesia
Description
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
Time Frame
3 month
Title
Patient Scar Assessment- Paresthesia
Description
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
Time Frame
6 month
Title
Patient Scar Assessment- Paresthesia
Description
Presence of paresthesia on a 1-10 scale , higher score denote worse outcomes
Time Frame
1 year
Title
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Description
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale. On a scale of 0-100; with higher score denotes worse outcome measure
Time Frame
pre-op
Title
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Description
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale. On a scale of 0-100; with higher score denotes worse outcome measure
Time Frame
3 month
Title
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Description
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale. On a scale of 0-100; with higher score denotes worse outcome measure
Time Frame
6 month
Title
The Disabilities of the Arm, Shoulder and Hand (QuickDASH) Questionnaire)
Description
Functional outcome as measured by pre and post operative assessment on the QuickDASH scale. On a scale of 0-100; with higher score denotes worse outcome measure
Time Frame
1 year
Title
Percent of Wound Contracture
Description
Planimetry Software will be used to measure and determine percentage of wound contracture
Time Frame
3 month
Title
Percent of Wound Contracture
Description
Planimetry Software will be used to measure and determine percentage of wound contracture
Time Frame
6 month
Title
Percent of Wound Contracture
Description
Planimetry Software will be used to measure and determine percentage of wound contracture
Time Frame
1 year
Title
Skin Pliability
Description
Skin pliability will be measuredusing a Cutometer MPA 580. We plan to measure Pliability (Ua), Elasticity (Ue), Retraction (Ur). Viscoelasticity (Uv), and Extension (Uf).
Time Frame
1 year
Other Pre-specified Outcome Measures:
Title
Patient Scar Assessment
Description
Total score (20-200). Higher scores denote worse outcomes.
Time Frame
3 month
Title
Patient Scar Assessment
Description
Total score (20-200). Higher scores denote worse outcomes.
Time Frame
6 month
Title
Patient Scar Assessment
Description
Total score (20-200). Higher scores denote worse outcomes.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All subjects who receive a radial forearm free flaps in the included time period, including subjects with head and neck cancer, traumatic defects, chronic wounds, or any other problems that require a radical forearm free flap for reconstruction. Have had a distal, anterograde fasciocutaneous flap Age ≥ 18 years Ability to understand and the willingness to sign an IRB-approved informed consent document. Smokers and tobacco users will be included in this study Exclusion Criteria: Subjects who have had an osteocutaneous or musculocutaneous flap. Subjects who have a radial forearm flap with a proximal skin flap or subjects that receive a "reverse" radial forearm flap Pregnant women will be excluded due to the lack of clinical studies evaluating INTEGRA template in pregnant women.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joseph Molnar, MD, PhD
Organizational Affiliation
Wake Forest University Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wake Forest University Health Sciences
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect

We'll reach out to this number within 24 hrs